REFERENCES
1. World Health Organization. Global strategy and action plan on ageing and health. 2017. Available from: https://www.who.int/publications/i/item/global-strategy-and-action-plan-on-ageing-and-health [Last accessed on 18 Mar 2025].
2. Linz D, Gawalko M, Betz K, et al. Atrial fibrillation: epidemiology, screening and digital health. Lancet Reg Health Eur. 2024;37:100786.
3. Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart failure with preserved ejection fraction: JACC scientific statement. J Am Coll Cardiol. 2023;81:1810-34.
4. Fauchier L, Bisson A, Bodin A. Heart failure with preserved ejection fraction and atrial fibrillation: recent advances and open questions. BMC Med. 2023;21:54.
5. Goette A, Kalman JM, Aguinaga L, et al. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Heart Rhythm. 2017;14:e3-40.
6. Goldberger JJ, Arora R, Green D, et al. Evaluating the atrial myopathy underlying atrial fibrillation: identifying the arrhythmogenic and thrombogenic substrate. Circulation. 2015;132:278-91.
7. Omote K, Borlaug BA. Left atrial myopathy in heart failure with preserved ejection fraction. Circ J. 2023;87:1039-46.
9. Inciardi RM, Claggett B, Minamisawa M, et al. Association of left atrial structure and function with heart failure in older adults. J Am Coll Cardiol. 2022;79:1549-61.
10. Inciardi RM, Wang W, Alonso A, et al. Cardiac mechanics and the risk of atrial fibrillation in a community-based cohort of older adults. Eur Heart J Cardiovasc Imaging. 2024;25:1686-94.
11. Maheshwari A, Norby FL, Inciardi RM, et al. Left atrial mechanical dysfunction and the risk for ischemic stroke in people without prevalent atrial fibrillation or stroke: a prospective cohort study. Ann Intern Med. 2023;176:39-48.
12. Wang W, Zhang MJ, Inciardi RM, et al. Association of echocardiographic measures of left atrial function and size with incident dementia. JAMA. 2022;327:1138-48.
13. Lamberts RR, Lingam SJ, Wang HY, et al. Impaired relaxation despite upregulated calcium-handling protein atrial myocardium from type 2 diabetic patients with preserved ejection fraction. Cardiovasc Diabetol. 2014;13:72.
14. Watanabe M, Yokoshiki H, Mitsuyama H, Mizukami K, Ono T, Tsutsui H. Conduction and refractory disorders in the diabetic atrium. Am J Physiol Heart Circ Physiol. 2012;303:H86-95.
15. Kato T, Yamashita T, Sekiguchi A, et al. AGEs-RAGE system mediates atrial structural remodeling in the diabetic rat. J Cardiovasc Electrophysiol. 2008;19:415-20.
16. Goette A, Lendeckel U, Kuchenbecker A, et al. Cigarette smoking induces atrial fibrosis in humans via nicotine. Heart. 2007;93:1056-63.
17. Xu TY, Sun JP, Lee AP, et al. Left atrial function as assessed by speckle-tracking echocardiography in hypertension. Medicine. 2015;94:e526.
18. Disertori M, Quintarelli S, Grasso M, et al. Autosomal recessive atrial dilated cardiomyopathy with standstill evolution associated with mutation of Natriuretic Peptide Precursor A. Circ Cardiovasc Genet. 2013;6:27-36.
19. Peng W, Li M, Li H, et al. Dysfunction of myosin light-chain 4 (MYL4) leads to heritable atrial cardiomyopathy with electrical, contractile, and structural components: evidence from genetically-engineered rats. J Am Heart Assoc. 2017;6:e007030.
20. Zhu Y, Shi J, Zheng B, et al. Genetic findings in patients with primary fibrotic atrial cardiomyopathy. Eur J Med Genet. 2022;65:104429.
21. Vergaro G, Aimo A, Rapezzi C, et al. Atrial amyloidosis: mechanisms and clinical manifestations. Eur J Heart Fail. 2022;24:2019-28.
22. Nochioka K, Quarta CC, Claggett B, et al. Left atrial structure and function in cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2017;18:1128-37.
23. Bandera F, Martone R, Chacko L, et al. Clinical importance of left atrial infiltration in cardiac transthyretin amyloidosis. JACC Cardiovasc Imaging. 2022;15:17-29.
24. Sanchis K, Cariou E, Colombat M, et al. Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality. Amyloid. 2019;26:128-38.
25. Feng D, Syed IS, Martinez M, et al. Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation. 2009;119:2490-7.
26. Dubrey S, Pollak A, Skinner M, Falk RH. Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation. Br Heart J. 1995;74:541-4.
27. El-Am EA, Dispenzieri A, Melduni RM, et al. Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis. J Am Coll Cardiol. 2019;73:589-97.
28. Feng D, Edwards WD, Oh JK, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation. 2007;116:2420-6.
29. Cappelli F, Tini G, Russo D, et al. Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation. Amyloid. 2021;28:12-8.
30. Singh A, Carvalho Singulane C, Miyoshi T, et al. Normal values of left atrial size and function and the impact of age: results of the world alliance societies of echocardiography study. J Am Soc Echocardiogr. 2022;35:154-64.e3.
31. Medrano G, Hermosillo-Rodriguez J, Pham T, et al. Left atrial volume and pulmonary artery diameter are noninvasive measures of age-related diastolic dysfunction in mice. J Gerontol A Biol Sci Med Sci. 2016;71:1141-50.
32. Pan NH, Tsao HM, Chang NC, Chen YJ, Chen SA. Aging dilates atrium and pulmonary veins: implications for the genesis of atrial fibrillation. Chest. 2008;133:190-6.
33. Eshoo S, Ross DL, Thomas L. Impact of mild hypertension on left atrial size and function. Circ Cardiovasc Imaging. 2009;2:93-9.
34. Pritchett AM, Mahoney DW, Jacobsen SJ, Rodeheffer RJ, Karon BL, Redfield MM. Diastolic dysfunction and left atrial volume: a population-based study. J Am Coll Cardiol. 2005;45:87-92.
35. Lin KB, Chen KK, Li S, et al. Impaired left atrial performance resulting from age-related arial fibrillation is associated with increased fibrosis burden: insights from a clinical study combining with an in vivo experiment. Front Cardiovasc Med. 2020;7:615065.
37. Jansen HJ, Moghtadaei M, Rafferty SA, Rose RA. Atrial fibrillation in aging and frail mice: modulation by natriuretic peptide receptor C. Circ Arrhythm Electrophysiol. 2021;14:e010077.
38. Takahashi Y, Yamaguchi T, Otsubo T, et al. Histological validation of atrial structural remodelling in patients with atrial fibrillation. Eur Heart J. 2023;44:3339-53.
39. Clarke JD, Caldwell JL, Pearman CM, Eisner DA, Trafford AW, Dibb KM. Increased Ca buffering underpins remodelling of Ca2+ handling in old sheep atrial myocytes. J Physiol. 2017;595:6263-79.
40. Hayashi H, Wang C, Miyauchi Y, et al. Aging-related increase to inducible atrial fibrillation in the rat model. J Cardiovasc Electrophysiol. 2002;13:801-8.
41. Wu L, Emmens RW, van Wezenbeek J, et al. Atrial inflammation in different atrial fibrillation subtypes and its relation with clinical risk factors. Clin Res Cardiol. 2020;109:1271-81.
42. Tan R, Yuan M, Wang L, et al. The pathogenesis of aging-induced left atrial appendage thrombus formation and cardioembolic stroke in mice is influenced by inflammation-derived matrix metalloproteinases. Thromb Res. 2023;226:69-81.
43. Wehrum T, Lodemann T, Hagenlocher P, et al. Age-related changes of right atrial morphology and inflow pattern assessed using 4D flow cardiovascular magnetic resonance: results of a population-based study. J Cardiovasc Magn Reson. 2018;20:38.
44. Jansen HJ, Moghtadaei M, Mackasey M, et al. Atrial structure, function and arrhythmogenesis in aged and frail mice. Sci Rep. 2017;7:44336.
46. Sugimoto T, Robinet S, Dulgheru R, et al. Echocardiographic reference ranges for normal left atrial function parameters: results from the EACVI NORRE study. Eur Heart J Cardiovasc Imaging. 2018;19:630-8.
47. Nyberg J, Jakobsen EO, Østvik A, et al. Echocardiographic reference ranges of global longitudinal strain for all cardiac chambers using guideline-directed dedicated views. JACC Cardiovasc Imaging. 2023;16:1516-31.
48. Zhang MJ, Gyberg DJ, Healy CL, et al. Atrial myopathy quantified by speckle-tracking echocardiography in mice. Circ Cardiovasc Imaging. 2023;16:e015735.
49. Abou R, Leung M, Tonsbeek AM, et al. Effect of aging on left atrial compliance and electromechanical properties in subjects without structural heart disease. Am J Cardiol. 2017;120:140-7.
50. Liao JN, Chao TF, Kuo JY, et al. Age, sex, and blood pressure-related influences on reference values of left atrial deformation and mechanics from a large-scale Asian population. Circ Cardiovasc Imaging. 2017;10:e006077.
51. Boyd AC, Schiller NB, Leung D, Ross DL, Thomas L. Atrial dilation and altered function are mediated by age and diastolic function but not before the eighth decade. JACC Cardiovasc Imaging. 2011;4:234-42.
52. Chen LY, Ribeiro ALP, Platonov PG, et al. P wave parameters and indices: a critical appraisal of clinical utility, challenges, and future research-a consensus document endorsed by the international society of electrocardiology and the international society for holter and noninvasive electrocardiology. Circ Arrhythm Electrophysiol. 2022;15:e010435.
53. Eranti A, Aro AL, Kerola T, et al. Prevalence and prognostic significance of abnormal P terminal force in lead V1 of the ECG in the general population. Circ Arrhythm Electrophysiol. 2014;7:1116-21.
54. Wolder LD, Graff C, Baadsgaard KH, et al. Electrocardiographic P terminal force in lead V1, its components, and the association with stroke and atrial fibrillation or flutter. Heart Rhythm. 2023;20:354-62.
55. Turhan H, Yetkin E, Sahin O, et al. Comparison of P-wave duration and dispersion in patients aged > 65 years with those aged < 45 years. J Electrocardiol. 2003;36:321-6.
56. Magnani JW, Johnson VM, Sullivan LM, et al. P wave duration and risk of longitudinal atrial fibrillation in persons ≥ 60 years old (from the Framingham Heart Study). Am J Cardiol. 2011;107:917-21.e1.
57. Soliman EZ, Prineas RJ, Case LD, Zhang ZM, Goff DC Jr. Ethnic distribution of ECG predictors of atrial fibrillation and its impact on understanding the ethnic distribution of ischemic stroke in the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2009;40:1204-11.
58. Achmad C, Tiksnadi BB, Akbar MR, et al. Left volume atrial index and P-wave dispersion as predictors of postoperative atrial fibrillation after coronary artery bypass graft: a retrospective cohort study. Curr Probl Cardiol. 2023;48:101031.
59. Materazzo C, Piotti P, Mantovani C, Miceli R, Villani F. Atrial fibrillation after non-cardiac surgery: P-wave characteristics and Holter monitoring in risk assessment. Eur J Cardiothorac Surg. 2007;31:812-6.
60. van der Does WFB, Houck CA, Heida A, et al. Atrial electrophysiological characteristics of aging. J Cardiovasc Electrophysiol. 2021;32:903-12.
61. Kistler PM, Sanders P, Fynn SP, et al. Electrophysiologic and electroanatomic changes in the human atrium associated with age. J Am Coll Cardiol. 2004;44:109-16.
62. Sim I, Bishop M, O'Neill M, Williams SE. Left atrial voltage mapping: defining and targeting the atrial fibrillation substrate. J Interv Card Electrophysiol. 2019;56:213-27.
63. Ahmed-Jushuf F, Murgatroyd F, Dhillon P, Scott PA. The impact of the presence of left atrial low voltage areas on outcomes from pulmonary vein isolation. J Arrhythm. 2019;35:205-14.
64. Yamaguchi T, Otsubo T, Takahashi Y, et al. Atrial structural remodeling in patients with atrial fibrillation is a diffuse fibrotic process: evidence from high-density voltage mapping and atrial biopsy. J Am Heart Assoc. 2022;11:e024521.
65. Emelyanova L, Preston C, Gupta A, et al. Effect of aging on mitochondrial energetics in the human atria. J Gerontol A Biol Sci Med Sci. 2018;73:608-16.
66. Nemutlu E, Gupta A, Zhang S, et al. Decline of phosphotransfer and substrate supply metabolic circuits hinders ATP cycling in aging myocardium. PLoS One. 2015;10:e0136556.
67. Lee HC, Shiou YL, Jhuo SJ, et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats. Cardiovasc Diabetol. 2019;18:45.
68. Franceschi C, Capri M, Monti D, et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev. 2007;128:92-105.
69. Thomas TP, Grisanti LA. The dynamic interplay between cardiac inflammation and fibrosis. Front Physiol. 2020;11:529075.
70. Mesquita TRR, Zhang R, de Couto G, et al. Mechanisms of atrial fibrillation in aged rats with heart failure with preserved ejection fraction. Heart Rhythm. 2020;17:1025-33.
71. Koh AS, Siau A, Gao F, et al. Left atrial phasic function in older adults is associated with fibrotic and low-grade inflammatory pathways. Gerontology. 2023;69:47-56.
72. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation. 1999;100:87-95.
73. Hopman LHGA, Mulder MJ, van der Laan AM, et al. Impaired left atrial reservoir and conduit strain in patients with atrial fibrillation and extensive left atrial fibrosis. J Cardiovasc Magn Reson. 2021;23:131.
74. Forsey RJ, Thompson JM, Ernerudh J, et al. Plasma cytokine profiles in elderly humans. Mech Ageing Dev. 2003;124:487-93.
75. Bonnema DD, Webb CS, Pennington WR, et al. Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J Card Fail. 2007;13:530-40.
76. Polejaeva IA, Ranjan R, Davies CJ, et al. Increased susceptibility to atrial fibrillation secondary to atrial fibrosis in transgenic goats expressing transforming growth factor-β1. J Cardiovasc Electrophysiol. 2016;27:1220-9.
77. Guzadhur L, Pearcey SM, Duehmke RM, et al. Atrial arrhythmogenicity in aged Scn5a+/DeltaKPQ mice modeling long QT type 3 syndrome and its relationship to Na+ channel expression and cardiac conduction. Pflugers Arch. 2010;460:593-601.
78. Baba S, Dun W, Hirose M, Boyden PA. Sodium current function in adult and aged canine atrial cells. Am J Physiol Heart Circ Physiol. 2006;291:H756-61.
79. Dun W, Yagi T, Rosen MR, Boyden PA. Calcium and potassium currents in cells from adult and aged canine right atria. Cardiovasc Res. 2003;58:526-34.
80. Nagibin V, Egan Benova T, Viczenczova C, et al. Ageing related down-regulation of myocardial connexin-43 and up-regulation of MMP-2 may predict propensity to atrial fibrillation in experimental animals. Physiol Res. 2016;65 Suppl 1:S91-S100.
81. Di Micco R, Krizhanovsky V, Baker D, d'Adda di Fagagna F. Cellular senescence in ageing: from mechanisms to therapeutic opportunities. Nat Rev Mol Cell Biol. 2021;22:75-95.
83. Hu C, Zhang X, Teng T, Ma ZG, Tang QZ. Cellular senescence in cardiovascular diseases: a systematic review. Aging Dis. 2022;13:103-28.
84. Jesel L, Abbas M, Park SH, et al. Atrial fibrillation progression is associated with cell senescence burden as determined by p53 and p16 expression. J Clin Med. 2019;9:36.
85. Tang X, Li PH, Chen HZ. Cardiomyocyte senescence and cellular communications within myocardial microenvironments. Front Endocrinol. 2020;11:280.
86. Anderson R, Lagnado A, Maggiorani D, et al. Length-independent telomere damage drives post-mitotic cardiomyocyte senescence. EMBO J. 2019;38:e100492.
87. Gao XY, Lai YY, Luo XS, et al. Acetyltransferase p300 regulates atrial fibroblast senescence and age-related atrial fibrosis through p53/Smad3 axis. Aging Cell. 2023;22:e13743.
88. Hasan H, Park SH, Auger C, et al. Thrombin induces angiotensin II-mediated senescence in atrial endothelial cells: impact on pro-remodeling patterns. J Clin Med. 2019;8:1570.
89. Sen P, Shah PP, Nativio R, Berger SL. Epigenetic mechanisms of longevity and aging. Cell. 2016;166:822-39.
90. Herman AB, Occean JR, Sen P. Epigenetic dysregulation in cardiovascular aging and disease. J Cardiovasc Aging. 2021;1:10.
91. Roberts JD, Vittinghoff E, Lu AT, et al. Epigenetic age and the risk of incident atrial fibrillation. Circulation. 2021;144:1899-911.
92. Lin H, Yin X, Xie Z, et al. Methylome-wide association study of atrial fibrillation in Framingham heart study. Sci Rep. 2017;7:40377.
93. Doñate Puertas R, Meugnier E, Romestaing C, et al. Atrial fibrillation is associated with hypermethylation in human left atrium, and treatment with decitabine reduces atrial tachyarrhythmias in spontaneously hypertensive rats. Transl Res. 2017;184:57-67.e5.
94. Lugenbiel P, Govorov K, Syren P, et al. Epigenetic regulation of cardiac electrophysiology in atrial fibrillation: HDAC2 determines action potential duration and suppresses NRSF in cardiomyocytes. Basic Res Cardiol. 2021;116:13.
95. Song S, Zhang R, Mo B, et al. EZH2 as a novel therapeutic target for atrial fibrosis and atrial fibrillation. J Mol Cell Cardiol. 2019;135:119-33.
96. Jusic A, Thomas PB, Wettinger SB, et al. Noncoding RNAs in age-related cardiovascular diseases. Ageing Res Rev. 2022;77:101610.
97. Varghese LN, Schwenke DO, Katare R. Role of noncoding RNAs in cardiac ageing. Front Cardiovasc Med. 2023;10:1142575.
98. Jazbutyte V, Fiedler J, Kneitz S, et al. MicroRNA-22 increases senescence and activates cardiac fibroblasts in the aging heart. Age. 2013;35:747-62.
99. Boon RA, Iekushi K, Lechner S, et al. MicroRNA-34a regulates cardiac ageing and function. Nature. 2013;495:107-10.
100. Trembinski DJ, Bink DI, Theodorou K, et al. Aging-regulated anti-apoptotic long non-coding RNA Sarrah augments recovery from acute myocardial infarction. Nat Commun. 2020;11:2039.
101. Adam O, Löhfelm B, Thum T, et al. Role of miR-21 in the pathogenesis of atrial fibrosis. Basic Res Cardiol. 2012;107:278.
102. Lu Y, Zhang Y, Wang N, et al. MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation. Circulation. 2010;122:2378-87.
103. Luo X, Pan Z, Shan H, et al. MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation. J Clin Invest. 2013;123:1939-51.
104. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271:840-4.
105. Vieira MJ, Teixeira R, Gonçalves L, Gersh BJ. Left atrial mechanics: echocardiographic assessment and clinical implications. J Am Soc Echocardiogr. 2014;27:463-78.
106. Lisi M, Mandoli GE, Cameli M, et al. Left atrial strain by speckle tracking predicts atrial fibrosis in patients undergoing heart transplantation. Eur Heart J Cardiovasc Imaging. 2022;23:829-35.
107. Patel DA, Lavie CJ, Milani RV, Shah S, Gilliland Y. Clinical implications of left atrial enlargement: a review. Ochsner J. 2009;9:191-6.
108. Kuppahally SS, Akoum N, Burgon NS, et al. Left atrial strain and strain rate in patients with paroxysmal and persistent atrial fibrillation: relationship to left atrial structural remodeling detected by delayed-enhancement MRI. Circ Cardiovasc Imaging. 2010;3:231-9.
109. Olsen FJ, Diederichsen SZ, Jørgensen PG, et al. Left atrial strain predicts subclinical atrial fibrillation detected by long-term continuous monitoring in elderly high-risk individuals. Circ Cardiovasc Imaging. 2024;17:e016197.
110. Mannina C, Ito K, Jin Z, et al. Association of left atrial strain with ischemic stroke risk in older adults. JAMA Cardiol. 2023;8:317-25.
111. Maffeis C, Rossi A, Cannata L, et al. Left atrial strain predicts exercise capacity in heart failure independently of left ventricular ejection fraction. ESC Heart Fail. 2022;9:842-52.
112. Jia F, Chen A, Zhang D, Fang L, Chen W. Prognostic value of left atrial strain in heart failure: a systematic review and meta-analysis. Front Cardiovasc Med. 2022;9:935103.
113. Donal E, Galli E, Schnell F. Left atrial strain: a must or a plus for routine clinical practice? Circ Cardiovasc Imaging. 2017;10:e007023.
114. Badano LP, Kolias TJ, Muraru D, et al. Standardization of left atrial, right ventricular, and right atrial deformation imaging using two-dimensional speckle tracking echocardiography: a consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. Eur Heart J Cardiovasc Imaging. 2018;19:591-600.
115. Pathan F, D'Elia N, Nolan MT, Marwick TH, Negishi K. Normal ranges of left atrial strain by speckle-tracking echocardiography: a systematic review and meta-analysis. J Am Soc Echocardiogr. 2017;30:59-70.e8.
116. Yuda S, Nakatani S, Isobe F, Kosakai Y, Miyatake K. Comparative efficacy of the maze procedure for restoration of atrial contraction in patients with and without giant left atrium associated with mitral valve disease. J Am Coll Cardiol. 1998;31:1097-102.
117. Vasan RS, Larson MG, Levy D, Galderisi M, Wolf PA, Benjamin EJ. National Heart; Lung; and Blood Institute; National Institutes of Health. Doppler transmitral flow indexes and risk of atrial fibrillation (the Framingham Heart Study). Am J Cardiol. 2003;91:1079-83.
118. Thomas L, Muraru D, Popescu BA, et al. Evaluation of left atrial size and function: relevance for clinical practice. J Am Soc Echocardiogr. 2020;33:934-52.
119. Khankirawatana B, Khankirawatana S, Peterson B, Mahrous H, Porter TR. Peak atrial systolic mitral annular velocity by Doppler tissue reliably predicts left atrial systolic function. J Am Soc Echocardiogr. 2004;17:353-60.
120. Siebermair J, Kholmovski EG, Marrouche N. Assessment of left atrial fibrosis by late gadolinium enhancement magnetic resonance imaging: methodology and clinical implications. JACC Clin Electrophysiol. 2017;3:791-802.
121. Whitaker J, Karády J, Karim R, et al. Standardised computed tomographic assessment of left atrial morphology and tissue thickness in humans. Int J Cardiol Heart Vasc. 2021;32:100694.
122. Romero J, Husain SA, Kelesidis I, Sanz J, Medina HM, Garcia MJ. Detection of left atrial appendage thrombus by cardiac computed tomography in patients with atrial fibrillation: a meta-analysis. Circ Cardiovasc Imaging. 2013;6:185-94.
123. Patel RB, Alenezi F, Sun JL, et al. Biomarker profile of left atrial myopathy in heart failure with preserved ejection fraction: insights from the RELAX trial. J Card Fail. 2020;26:270-5.
124. Guo J, Huang X, Dou L, et al. Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. Signal Transduct Target Ther. 2022;7:391.
125. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380:37-43.
126. Rivner H, Mitrani RD, Goldberger JJ. Atrial myopathy underlying atrial fibrillation. Arrhythm Electrophysiol Rev. 2020;9:61-70.
127. Kallergis EM, Goudis CA, Vardas PE. Atrial fibrillation: a progressive atrial myopathy or a distinct disease? Int J Cardiol. 2014;171:126-33.
128. Kornej J, Börschel CS, Benjamin EJ, Schnabel RB. Epidemiology of Atrial fibrillation in the 21st century: novel methods and new insights. Circ Res. 2020;127:4-20.
129. Khurshid S, Ashburner JM, Ellinor PT, et al. Prevalence and incidence of atrial fibrillation among older primary care patients. JAMA Netw Open. 2023;6:e2255838.
130. Granada J, Uribe W, Chyou PH, et al. Incidence and predictors of atrial flutter in the general population. J Am Coll Cardiol. 2000;36:2242-6.
131. Waldo AL. Inter-relationships between atrial flutter and atrial fibrillation. Pacing Clin Electrophysiol. 2003;26:1583-96.
132. Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology. 1978;28:973-7.
133. Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ. 2016;354:i4482.
134. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946-52.
135. Redfield MM, Borlaug BA. Heart failure with preserved ejection fraction: a review. JAMA. 2023;329:827-38.
136. Melenovsky V, Hwang SJ, Redfield MM, Zakeri R, Lin G, Borlaug BA. Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction. Circ Heart Fail. 2015;8:295-303.
137. Patel RB, Lam CSP, Svedlund S, et al. Disproportionate left atrial myopathy in heart failure with preserved ejection fraction among participants of the PROMIS-HFpEF study. Sci Rep. 2021;11:4885.
138. Tamargo M, Obokata M, Reddy YNV, et al. Functional mitral regurgitation and left atrial myopathy in heart failure with preserved ejection fraction. Eur J Heart Fail. 2020;22:489-98.
139. Deedwania PC, Lardizabal JA. Atrial fibrillation in heart failure: a comprehensive review. Am J Med. 2010;123:198-204.
140. Smietana J, Plitt A, Halperin JL. Thromboembolism in the absence of atrial fibrillation. Am J Cardiol. 2019;124:303-11.
141. Brambatti M, Connolly SJ, Gold MR, et al. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation. 2014;129:2094-9.
142. Souza JB, Sousa MG, Laurinavicius AG, et al. Advanced echocardiography techniques (AETs) to assess left atrial structure and function in individuals with resistant hypertension. Echocardiography. 2023;40:792-801.
143. Vera A, Cecconi A, Ximénez-Carrillo Á, et al. Advanced echocardiography with left atrial strain and indexed left atrial three-dimensional volume for predicting underlying atrial fibrillation after cryptogenic stroke. Am J Cardiol. 2022;185:87-93.
144. Peters DC, Lamy J, Sinusas AJ, Baldassarre LA. Left atrial evaluation by cardiovascular magnetic resonance: sensitive and unique biomarkers. Eur Heart J Cardiovasc Imaging. 2021;23:14-30.
145. Pay L, Yumurtaş AÇ, Satti DI, et al. Arrhythmias beyond atrial fibrillation detection using smartwatches: a systematic review. Anatol J Cardiol. 2023;27:126-31.
146. Mannhart D, Lischer M, Knecht S, et al. Clinical validation of 5 direct-to-consumer wearable smart devices to detect atrial fibrillation: BASEL wearable study. JACC Clin Electrophysiol. 2023;9:232-42.
147. Verbrugge FH, Reddy YNV, Attia ZI, et al. Detection of left atrial myopathy using artificial intelligence-enabled electrocardiography. Circ Heart Fail. 2022;15:e008176.
148. Yuan N, Stein NR, Duffy G, et al. Deep learning evaluation of echocardiograms to identify occult atrial fibrillation. NPJ Digit Med. 2024;7:96.
149. Aquino GJ, Chamberlin J, Yacoub B, et al. Diagnostic accuracy and performance of artificial intelligence in measuring left atrial volumes and function on multiphasic CT in patients with atrial fibrillation. Eur Radiol. 2022;32:5256-64.
150. Pieszko K, Hiczkiewicz J, Łojewska K, et al. Artificial intelligence in detecting left atrial appendage thrombus by transthoracic echocardiography and clinical features: the Left Atrial Thrombus on Transoesophageal Echocardiography (LATTEE) registry. Eur Heart J. 2024;45:32-41.
151. Oakes RS, Badger TJ, Kholmovski EG, et al. Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation. 2009;119:1758-67.
152. Marrouche NF, Wilber D, Hindricks G, et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA. 2014;311:498-506.
153. Marrouche NF, Wazni O, McGann C, et al. Effect of MRI-guided fibrosis ablation vs conventional catheter ablation on atrial arrhythmia recurrence in patients with persistent atrial fibrillation: The DECAAF II randomized clinical trial. JAMA. 2022;327:2296-305.
154. Takemoto Y, Barnes ME, Seward JB, et al. Usefulness of left atrial volume in predicting first congestive heart failure in patients > 65 years of age with well-preserved left ventricular systolic function. Am J Cardiol. 2005;96:832-6.
155. Osranek M, Fatema K, Qaddoura F, et al. Left atrial volume predicts the risk of atrial fibrillation after cardiac surgery: a prospective study. J Am Coll Cardiol. 2006;48:779-86.
156. Beinart R, Boyko V, Schwammenthal E, et al. Long-term prognostic significance of left atrial volume in acute myocardial infarction. J Am Coll Cardiol. 2004;44:327-34.
157. Thadani SR, Shaw RE, Fang Q, Whooley MA, Schiller NB. Left atrial end-diastolic volume index as a predictor of cardiovascular outcomes: the heart and soul study. Circ Cardiovasc Imaging. 2020;13:e009746.
158. Shin SH, Claggett B, Inciardi RM, et al. Prognostic value of minimal left atrial volume in heart failure with preserved ejection fraction. J Am Heart Assoc. 2021;10:e019545.
159. Kreimer F, Gotzmann M. Left atrial cardiomyopathy - a challenging diagnosis. Front Cardiovasc Med. 2022;9:942385.
160. Olsen FJ, Bertelsen L, de Knegt MC, et al. Multimodality cardiac imaging for the assessment of left atrial function and the association with atrial arrhythmias. Circ Cardiovasc Imaging. 2016;9:e004947.
161. Babuin L. Troponin: the biomarker of choice for the detection of cardiac injury. Can Med Assoc J. 2005;173:1191-202.
162. Mueller C, McDonald K, de Boer RA, et al. Heart failure association of the european society of cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21:715-31.
163. Kennedy JW, Yarnall SR, Murray JA, Figley MM. Quantitative angiocardiography. IV. Relationships of left atrial and ventricular pressure and volume in mitral valve disease. Circulation. 1970;41:817-24.
164. Zile MR, Gottdiener JS, Hetzel SJ, et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation. 2011;124:2491-501.
165. Rienstra M, Hobbelt AH, Alings M, et al. Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial. Eur Heart J. 2018;39:2987-96.
166. Patel RB, Shah SJ. Therapeutic targeting of left atrial myopathy in atrial fibrillation and heart failure with preserved ejection fraction. JAMA Cardiol. 2020;5:497-9.
167. Milliez P, Deangelis N, Rucker-Martin C, et al. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J. 2005;26:2193-9.
168. Shantsila E, Shahid F, Sun Y, et al. Spironolactone in atrial fibrillation with preserved cardiac fraction: the IMPRESS-AF trial. J Am Heart Assoc. 2020;9:e016239.
169. Feldman T, Mauri L, Kahwash R, et al. Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction (REDUCE LAP-HF I [reduce elevated left atrial pressure in patients with heart failure]): a phase 2, randomized, sham-controlled trial. Circulation. 2018;137:364-75.
170. Simard T, Labinaz M, Zahr F, et al. Percutaneous atriotomy for levoatrial-to-coronary sinus shunting in symptomatic heart failure: first-in-human experience. JACC Cardiovasc Interv. 2020;13:1236-47.
171. Voors AA, Tamby JF, Cleland JG, et al. Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. Eur J Heart Fail. 2020;22:1649-58.
172. Kumar M, Yan P, Kuchel GA, Xu M. Cellular senescence as a targetable risk factor for cardiovascular diseases: therapeutic implications: JACC family series. JACC Basic Transl Sci. 2024;9:522-34.
173. Marcoux E, Sosnowski D, Ninni S, et al. Genetic atrial cardiomyopathies: common features, specific differences, and broader relevance to understanding atrial cardiomyopathy. Circ Arrhythm Electrophysiol. 2023;16:675-98.
174. Roselli C, Rienstra M, Ellinor PT. Genetics of atrial fibrillation in 2020: GWAS, genome sequencing, polygenic risk, and beyond. Circ Res. 2020;127:21-33.
175. Hart RG, Catanese L, Perera KS, Ntaios G, Connolly SJ. Embolic stroke of undetermined source: a systematic review and clinical update. Stroke. 2017;48:867-72.
176. Kamel H, Longstreth WT Jr, Tirschwell DL, et al. Apixaban to prevent recurrence after cryptogenic stroke in patients with atrial cardiopathy: the ARCADIA randomized clinical trial. JAMA. 2024;331:573-81.
177. Marcus GM, Ovbiagele B. Anticoagulation for atrial cardiopathy in cryptogenic stroke. JAMA. 2024;331:564-6.
178. Chi KY, Nanna M, Nanna MG. Apixaban to prevent recurrence after cryptogenic stroke. JAMA. 2024;331:1965-6.
